Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium 10 October 2024 Avacta Group plc(“Avacta” or “the Group” or “the Company”) Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024...

Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium 10 OctoberAvacta Group plc(“Avacta” or “the Group” or “the Company”)Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium...

Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics — Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with...

Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.

Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 5 October 2023 Avacta Group plc (“Avacta” or the “Group” or the “Company”) Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International...